The effect of ZD1839 (Iressa(TM)), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC‐15 cells

Ítems similars

• Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)
  per: Sewell, J M, et al.
  Publicat: (2002)
• Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
  per: Blackledge, G, et al.
  Publicat: (2004)
• Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil
  per: Magné, N, et al.
  Publicat: (2003)
• Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines
  per: Maddineni, S B, et al.
  Publicat: (2005)
• ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model
  per: Williams, K J, et al.
  Publicat: (2002)